Tresaderm ® (thiabendazole, dexamethasone, neomycin sulfate solution)

Manufacturer
Boehringer Ingelheim Animal Health USA Inc.
Effective date
2023-11-17
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-06-01 02:42:29

Label at a glance#

ProductTRESADERM
Active ingredientdexamethasone, neomycin sulfate, thiabendazole
Label structure11 sections

Dosage and administration

Prior to the administration of Dermatologic Solution TRESADERM, remove the ceruminous, purulent or foreign materials from the ear canal, as well as the crust which may be associated with dermatoses affecting other parts of the body. The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon ...

Storage and handling

Store in a refrigerator 36 - 46°F (2 - 8°C).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Dermatologic Solution

Approved by FDA under NADA # 042-633

CAUTION

SPL UNCLASSIFIED SECTION

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

DESCRIPTION SECTION

Dermatologic Solution TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) contains the following active ingredients per mL: 40 mg thiabendazole, 1 mg dexamethasone, 3.2 mg neomycin (from neomycin sulfate). Inactive ingredients: glycerin, propylene glycol, purified water, hypophosphorous acid, calcium hypophosphite; about 8.5% ethyl alcohol and about 0.5% benzyl alcohol.

INDICATIONS

VETERINARY INDICATIONS SECTION

Dermatologic Solution TRESADERM is indicated as an aid in the treatment of certain bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs and cats. Both acute and chronic forms of these skin disorders respond to treatment with TRESADERM. Many forms of dermatosis are caused by bacteria (chiefly Staphylococcus aureus, Proteus vulgaris and Pseudomonas aeruginosa). Moreover, these organisms often act as opportunistic or concurrent pathogens that may complicate already established mycotic skin disorders, or otoacariasis caused by Otodectes cynotis. The principal etiologic agents of dermatomycoses in dogs and cats are species of the genera Microsporum and Trichophyton. The efficacy of neomycin as an antibacterial agent, with activity against both gram-negative and gram-positive pathogens, is well documented. Detailed studies in various laboratories have verified the significant activity thiabendazole displays against the important dermatophytes. Dexamethasone, a synthetic adrenocorticoid steroid, inhibits the reaction of connective tissue to injury and suppresses the classic inflammatory manifestations of skin disease. The formulation for TRESADERM combines these several activities in a complementary form for control of the discomfort and direct treatment of dermatitis and otitis externa produced by the above-mentioned infectious agents.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Prior to the administration of Dermatologic Solution TRESADERM, remove the ceruminous, purulent or foreign materials from the ear canal, as well as the crust which may be associated with dermatoses affecting other parts of the body. The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon the severity and extent of the lesions. Five to 15 drops should be instilled in the ear twice daily. In treating dermatoses affecting other than the ear the surface of the lesions should be well moistened (2 to 4 drops per square inch) with Dermatologic Solution TRESADERM twice daily. The volume required will be dependent upon the size of the lesion.

Application of TRESADERM should be limited to a period of not longer than one week.

PRECAUTIONS

PRECAUTIONS SECTION

On rare occasions dogs may be sensitive to neomycin. In these animals, application of the drug will result in erythema of the treated area, which may last 24 to 48 hours. Also, evidence of transient discomfort has been noted in some dogs when the drug was applied to fissured or denuded areas. The expression of pain may last 2 to 5 minutes. Application of Dermatologic Solution TRESADERM should be limited to periods not longer than one week.

While systemic side effects are not likely with topically applied corticosteroids, such a possibility should be considered if use of the solution is extensive and prolonged. If signs of salt and water retention or potassium excretion are noticed (increased thirst, weakness, lethargy, oliguria, gastrointestinal disturbances or tachycardia), treatment should be discontinued and appropriate measures taken to correct the electrolyte and fluid imbalance.

STORAGE AND HANDLING SECTION

Store in a refrigerator 36 - 46°F (2 - 8°C).

WARNING

WARNINGS SECTION

For topical use in dogs and cats.
Avoid contact with eyes.

Keep this and all drugs out of the reach of children.

The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or online at www.fda.gov/reportanimalae.

HOW SUPPLIED

HOW SUPPLIED SECTION

Products 128740 & 128741 - Dermatologic Solution TRESADERM Veterinary is supplied in 7.5 mL and 15 mL dropper bottles, each in 12 bottle boxes.

SPL UNCLASSIFIED SECTION

Marketed by
Boehringer Ingelheim Animal Health USA Inc.
Duluth, Georgia 30096

© 2019 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

October 2018

®TRESADERM is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.

PRINCIPAL DISPLAY PANEL - 15 mL Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Tresaderm®
(thiabendazole, dexamethasone,neomycin sulfate solution)

Dermatologic Solutionfor Dogs and Cats

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

12 x 15 mL Bottles

Principal Display Panel - 15 mL Bottle Carton
Principal Display Panel - 15 mL Bottle Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1009388thiabendazole 40 MG / dexAMETHasone 1 MG / neomycin 3.2 MG in ML Topical SolutionPSN3
1009392Tresaderm 40 MG / 1 MG / 3.2 MG in ML Topical SolutionPSN3
1009392dexamethasone 1 MG/ML / neomycin 3.2 MG/ML / thiabendazole 40 MG/ML Topical Solution [Tresaderm]SBD3
1009388dexamethasone 1 MG/ML / neomycin 3.2 MG/ML / thiabendazole 40 MG/ML Topical SolutionSCD3
1009388dexamethasone 1 MG / neomycin 3.2 MG / thiabendazole 40 MG per ML Topical SolutionSY3
1009392Tresaderm (dexamethasone 1 MG / neomycin 3.2 MG / thiabendazole 40 MG) per ML Topical SolutionSY3

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
1ea46721-9071-6b81-fd0a-a82bfbb014ecProduct name720250220
525701df-f985-480d-995a-e0ee70c2bdf4Product name520250128
ea50b939-d92a-4100-84f5-1c1089663837Product name220240705
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
d7d46a10-8766-d3c8-ebf2-2ccd9efdcae8Product name220220506
7b2c58e8-5850-4e3e-82e9-b1593b1de761Product name520220210
81e34474-b0a5-434f-8104-25d689efc99eProduct name120200303
05ab9c01-cd9a-4f59-b2e8-ddcb887cac39Product name120190408
0c7dba41-c919-5809-508d-4affe6cfcff2Product name220170817
99e684e6-f435-feb8-d2bb-3a546f1cb768Product name220161117
399647c0-db89-02d1-991c-0c17b584482cProduct name120140508
3e9a6377-704f-dff7-b19f-56c98d40c444Product name120140508
4d2e6ff9-14f5-b84f-c39b-373b005712c1Product name120140508
725d71bf-f956-5cad-e556-fa39cb060dc8Product name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
b6082387-f592-1148-0844-bd068fd213fbProduct name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0010-5587-01TRESADERM7.5 mL in 1 BOTTLE, WITH APPLICATORSOLUTION7.53
0010-5587-02TRESADERM12 in 1 CARTONSOLUTION123
0010-5587-03TRESADERM15 mL in 1 BOTTLE, WITH APPLICATORSOLUTION153
0010-5587-04TRESADERM12 in 1 CARTONSOLUTION123

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0010-5587TRESADERM (THIABENDAZOLE, DEXAMETHASONE, NEOMYCIN SULFATE) SOLUTION [BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.]34 package rows20231118_dfd55764-a280-45a0-a430-405ee7d7df40.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0010-55870010-5587-01, 0010-5587-02, 0010-5587-03, 0010-5587-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 5 · 86 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DexamethasoneDEXAMETHASONEREMEDYREPACK INC.8c5375a7-7a0d-4af0-8b86-bc87698ac3d12026-09-04Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONESportpharm LLCa37486b9-4323-41fc-ac7e-869d95dc95682026-07-17Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEREMEDYREPACK INC.f5c9b70b-b835-4f3b-9643-0aec50a0d3f22026-07-07Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPangea Pharmaceuticals, LLCa41e6e26-9ebb-4b06-866e-a24af21c644c2026-06-29Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPD-Rx Pharmaceuticals, Inc.89e1d458-7caa-430f-9c54-360889899a732026-06-12Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPD-Rx Pharmaceuticals, Inc.736861fa-1df8-4afd-ba4a-dd7d7bffd8652026-06-12Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPreferred Pharmaceuticals Inc79b65fd4-16a5-42e0-b041-61d7bda0a5ff2026-06-08Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEREMEDYREPACK INC.8deaaaf7-3efd-4065-b29f-e5ef038030f82026-06-01Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONECardinal Health 107, LLCbf8acfdb-8dc8-4a69-90b0-33c680c421d62026-05-15Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
dexamethasoneDEXAMETHASONECardinal Health 107, LLC5622f8d2-1893-441b-8011-fa90c8a63b0b2026-05-05Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONESportpharm LLC12d19271-867b-41ae-a6d2-7e8de36370112026-04-24Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPangea Pharmaceuticals, LLC37607468-0331-44c0-9bb4-5c614c7b69d42026-04-19Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
dexamethasoneDEXAMETHASONEPreferred Pharmaceuticals Inc.4c619d48-8cf9-4085-8405-c8f066bce19c2026-04-01Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEPreferred Pharmaceuticals, Inc.c4d1e578-a1d2-4d5e-8426-6b2c39f0d9bd2026-04-01Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
dexamethasoneDEXAMETHASONEMajor Pharmaceuticals64b46398-9b97-45e8-b1ba-1a202d5744482026-03-26Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
OZURDEXDEXAMETHASONEAllergan, Inc.4b204f44-6e8a-4d17-803c-268f0b04679f2026-03-11Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DEXAMETHASONEDEXAMETHASONENuCare Pharmaceuticals, Inc.4a808dd5-35b7-e879-e063-6394a90a0bf72026-02-10Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEDirect_Rx0a0db8e7-8474-3d08-e063-6294a90af3f52026-02-06Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEBryant Ranch Prepacke830be9d-0a8c-4712-93c6-284c208d6f0d2026-02-05Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE
DexamethasoneDEXAMETHASONEBryant Ranch Prepackb3217057-5945-452c-aa99-ab696fd8b5e72026-02-04Warnings, Adverse reactionsName fallback
generic name: DEXAMETHASONE

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.